Ultragenyx Pharmaceutical reported $136 million in total revenue for Q1 2026, with key products Crysvita and Dojolvi contributing $93 million and $18 million respectively. The company reaffirmed its 2026 revenue guidance of $730 million to $760 million and expects combined R&D and SG&A expenses to remain flat or slightly decrease compared to 2025. Ultragenyx highlighted promising long-term Phase 1/2 data for GTX-102 in treating Angelman syndrome, with Phase 3 results expected in the second half of 2026. The company is also progressing with regulatory reviews for gene therapies DTX401 and UX111, targeting approvals later this year, and aims for profitability in 2027.
A three-day online training on Pharmaceutical Regulatory Affairs in Asia is scheduled for October 20-22, 2026, aiming to help professionals understand diverse regulatory requirements across major Asian markets including China, India, Korea, and ASEAN...
The global workwear market, valued at $265.12 billion in 2025, is expected to grow to $344.71 billion by 2031 with a 4.5% CAGR. Growth is fueled by rising corporate employment worldwide, especially in Asia-Pacific, and increased focus on professional...
The global microalgae-based aquafeed market is projected to grow from $320 million in 2026 to $481 million by 2031, at an 8.5% CAGR. Key growth drivers include rapid cost reductions in closed photobioreactor farming, making algae competitive with fis...
The global consumer finance market is projected to expand from $9.87 trillion in 2025 to $14.08 trillion by 2031, growing at a 6.17% CAGR. Key growth drivers include embedded finance at point-of-sale, which boosts credit uptake by integrating lending...
Xcel Brands has signed a licensing agreement with KBL Group to produce ready-to-wear collections for OFF/DUTY by Coco Rocha, a fashion brand created with supermodel Coco Rocha. KBL Group will handle sourcing, product development, manufacturing, and s...
